MX375673B - Ensayos basados en interrogatorios celulares y usos de los mismos. - Google Patents

Ensayos basados en interrogatorios celulares y usos de los mismos.

Info

Publication number
MX375673B
MX375673B MX2018002069A MX2018002069A MX375673B MX 375673 B MX375673 B MX 375673B MX 2018002069 A MX2018002069 A MX 2018002069A MX 2018002069 A MX2018002069 A MX 2018002069A MX 375673 B MX375673 B MX 375673B
Authority
MX
Mexico
Prior art keywords
interrogations
cellular
essays
essays based
cancer
Prior art date
Application number
MX2018002069A
Other languages
English (en)
Inventor
Min Du
Niven Rajin Narain
Rangaprasad Sarangarajan
Tony Walshe
Vivek K Vishnudas
Original Assignee
Berg Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Llc filed Critical Berg Llc
Publication of MX375673B publication Critical patent/MX375673B/es

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)

Abstract

La presente invención se refiere a un descubrimiento de Tecnología de plataforma para analizar un sistema biológico o proceso (por ejemplo, una condición de enfermedad, tal como cáncer) mediante la construcción de un modelo.
MX2018002069A 2012-04-02 2012-09-07 Ensayos basados en interrogatorios celulares y usos de los mismos. MX375673B (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261619326P 2012-04-02 2012-04-02
US201261620305P 2012-04-04 2012-04-04
US201261665631P 2012-06-28 2012-06-28
US201261668617P 2012-07-06 2012-07-06
US201261678590P 2012-08-01 2012-08-01
US201261678596P 2012-08-01 2012-08-01
PCT/US2012/054321 WO2013151577A1 (en) 2012-04-02 2012-09-07 Interrogatory cell-based assays and uses thereof

Publications (1)

Publication Number Publication Date
MX375673B true MX375673B (es) 2025-03-06

Family

ID=49235335

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018002069A MX375673B (es) 2012-04-02 2012-09-07 Ensayos basados en interrogatorios celulares y usos de los mismos.
MX2014011797A MX357392B (es) 2012-04-02 2012-09-07 Ensayos basados en interrogatorios celulares y uso de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014011797A MX357392B (es) 2012-04-02 2012-09-07 Ensayos basados en interrogatorios celulares y uso de los mismos.

Country Status (14)

Country Link
US (2) US10061887B2 (es)
EP (1) EP2834366B1 (es)
JP (3) JP6189926B2 (es)
KR (2) KR102149070B1 (es)
CN (3) CN108048521B (es)
AU (2) AU2012376214B2 (es)
BR (1) BR112014024537A2 (es)
CA (1) CA2869296A1 (es)
EA (1) EA038600B1 (es)
HK (1) HK1209161A1 (es)
IL (1) IL234920B (es)
MX (2) MX375673B (es)
SG (2) SG10201608234UA (es)
WO (1) WO2013151577A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012119129A1 (en) 2011-03-02 2012-09-07 Berg Biosystems, Llc Interrogatory cell-based assays and uses thereof
MX375673B (es) 2012-04-02 2025-03-06 Berg Llc Ensayos basados en interrogatorios celulares y usos de los mismos.
EP2668945A1 (de) * 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
US9449284B2 (en) * 2012-10-04 2016-09-20 Nec Corporation Methods and systems for dependency network analysis using a multitask learning graphical lasso objective function
CN103558354B (zh) 2013-11-15 2015-07-15 南京大学 一种基于生物组学整合技术的水体毒性分析方法
EP3158487A1 (en) * 2014-06-20 2017-04-26 Connecticut Children's Medical Center Automated cell culture system and corresponding methods
CA2960837A1 (en) 2014-09-11 2016-03-17 Berg Llc Bayesian causal relationship network models for healthcare diagnosis and treatment based on patient data
CN105624275B (zh) * 2014-11-06 2020-03-27 上海市东方医院 Eif4g1在鳞癌诊断和治疗中的应用
JP6270221B2 (ja) * 2015-02-13 2018-01-31 国立研究開発法人産業技術総合研究所 バイオマーカー探索方法、バイオマーカー探索装置、及びプログラム
KR101786859B1 (ko) * 2015-04-30 2017-10-17 서울대학교산학협력단 혈장 내 아밀로이드베타의 농도를 통해 알츠하이머병을 임상학적 및 병리학적으로 모니터링하는 방법
US10395759B2 (en) 2015-05-18 2019-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for copy number variant detection
WO2016190743A1 (en) * 2015-05-28 2016-12-01 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Assays to identify genetic elements affecting phenotype
CN106250717B (zh) * 2015-06-04 2019-03-12 徐勇 急性髓性白血病的miRNA与转录因子的系统及其构建方法和应用
US20160363567A1 (en) * 2015-06-15 2016-12-15 Lunatech, Llc Vapor Device For Stressing And Analyzing Compounds
WO2017065127A1 (ja) * 2015-10-14 2017-04-20 公立大学法人横浜市立大学 腎癌薬物療法の効果判定のための血中バイオマーカー
CA3014292A1 (en) 2016-02-12 2017-08-17 Regeneron Pharmaceuticals, Inc. Methods and systems for detection of abnormal karyotypes
FI3469338T3 (fi) * 2016-06-10 2025-05-06 Univ California Kuvapohjaisia solunlajittelujärjestelmiä ja -menetelmiä
EP3538095A4 (en) 2016-11-14 2020-06-17 Berg LLC Methods for treating parkinson's disease
CN106834105A (zh) * 2017-02-21 2017-06-13 齐齐哈尔医学院 一种用于表观遗传分析的设备和方法
US11636917B2 (en) * 2017-06-28 2023-04-25 The Regents Of The University Of California Simulating the metabolic pathway dynamics of an organism
CN107475346B (zh) * 2017-08-11 2021-08-06 北京汉典制药有限公司 一种体外筛选糖尿病肾病药物的方法
JP6902977B2 (ja) * 2017-09-22 2021-07-14 新日本無線株式会社 起動回路の故障検出方法
AU2018351147B2 (en) * 2017-10-18 2025-07-10 Venn Biosciences Corporation Identification and use of biological parameters for diagnosis and treatment monitoring
JP2021073432A (ja) * 2018-03-02 2021-05-13 国立研究開発法人医薬基盤・健康・栄養研究所 治療標的である活性化キナーゼのスクリーニング方法
JP7176381B2 (ja) * 2018-12-03 2022-11-22 富士通株式会社 環状分子の構造探索方法、及び構造探索装置、並びにプログラム
CN109536473A (zh) * 2018-12-19 2019-03-29 华中科技大学鄂州工业技术研究院 整合多组学数据推测细胞转分化中关键蛋白质激酶的方法
CA3128973A1 (en) 2019-03-04 2020-09-10 Bhaskar Bhattacharyya Data compression and communication using machine learning
US20210080466A1 (en) * 2019-06-26 2021-03-18 Berg Llc Markers for the diagnosis of prostate cancer
AU2021236148A1 (en) * 2020-03-10 2022-10-13 AI:ON Innovations, Inc. System and methods for mammalian transfer learning
WO2021251331A1 (ja) * 2020-06-08 2021-12-16 国立大学法人 東京医科歯科大学 標的分子予測方法
JP7735624B2 (ja) * 2020-08-31 2025-09-09 武田薬品工業株式会社 推論装置、推論方法、推論プログラム、モデル生成方法、推論サービス提供システム、推論サービス提供方法及び推論サービス提供プログラム
US11227690B1 (en) * 2020-09-14 2022-01-18 Opendna Ltd. Machine learning prediction of therapy response
CN113035298B (zh) * 2021-04-02 2023-06-20 南京信息工程大学 递归生成大阶数行限制覆盖阵列的药物临床试验设计方法
CN113138249B (zh) * 2021-04-12 2021-11-23 北京蛋白质组研究中心 基于微孔阵列芯片的微量样本代谢组、蛋白质组和磷酸化蛋白质组多组学分析方法
EP4338163A4 (en) * 2021-05-13 2024-11-06 Scipher Medicine Corporation ASSESSMENT OF RESPONSE TO THERAPY
CN113943720B (zh) * 2021-11-03 2025-09-16 江苏省农业科学院 一种绿盲蝽GRK基因、其dsRNA及其合成方法和应用
US20250322901A1 (en) * 2022-05-27 2025-10-16 Memorial Sloan-Kettering Cancer Center Systems and methods for metabolite imputation
CN117417914A (zh) * 2022-07-18 2024-01-19 华东师范大学 预防和保护脑缺血疾病的标志物及阿司匹林衍生物在预防和保护脑缺血疾病中的应用
WO2024081570A1 (en) * 2022-10-10 2024-04-18 Eli Lilly And Company Methods and systems for using causal networks to develop models for evaluating biological processes
EP4602611A1 (en) * 2022-10-13 2025-08-20 SomaLogic Operating Co., Inc. Systems and methods for validation of proteomic models
EP4688803A1 (en) * 2023-04-07 2026-02-11 The Medical College of Wisconsin, Inc. Compositions and methods for treatment or preventative treatment of cancer including triple negative breast cancer and/or lung cancer
CN117133375B (zh) * 2023-07-24 2025-05-30 浙江大学 一种基于机器学习的致肥胖化学品预测方法及装置
KR102763225B1 (ko) * 2023-09-26 2025-02-07 주식회사 그래디언트바이오컨버전스 최적의 오가노이드 배양배지 조합 결정 장치, 배양배지 조합들에 대한 생존율을 산출하여 최적의 조합을 결정하는 방법, 및 컴퓨터 프로그램
KR102763227B1 (ko) * 2023-09-26 2025-02-07 주식회사 그래디언트바이오컨버전스 최적의 줄기 세포 배양배지 조합 결정 장치, 배양배지 조합들에 대한 분화 성공률을 산출하여 최적의 조합을 결정하는 방법, 및 컴퓨터 프로그램
CN120405134A (zh) * 2024-01-30 2025-08-01 抟相医药(杭州)有限公司 基于凝聚体荧光漂白恢复技术(Drop-FRAP)的生物大分子相互作用调节剂筛选平台
CN118607082A (zh) * 2024-08-09 2024-09-06 成都理工大学 一种基于深度学习的压裂过程中套管变形的预测方法
CN119120480B (zh) * 2024-10-17 2025-04-29 山东省农业科学院畜牧兽医研究所 一种用于华西牛育种调节的环状rna及其应用
CN121324642B (zh) * 2025-12-10 2026-03-13 四川省医学科学院·四川省人民医院 一种用于检测乳酸化pgk1的双抗体连接探针、制备方法及应用

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6121424A (en) 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5621083A (en) 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
DE69233501T2 (de) 1991-11-22 2006-02-23 Affymetrix, Inc. (n.d.Ges.d.Staates Delaware), Santa Clara Kombinatorische Strategien für die Polymersynthese
DE69326967T2 (de) 1992-01-17 2000-06-15 Lakowicz, Joseph R. Phasenmodulationsenergieübertragungsfluoroimmunassay
US5918200A (en) 1992-08-31 1999-06-29 Yamatake-Honeywell Co., Ltd. State estimating apparatus
CA2153387A1 (en) 1993-01-07 1994-07-21 Hubert Koester Dna sequencing by mass spectrometry
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
ATE220114T1 (de) 1993-03-19 2002-07-15 Sequenom Inc Dns-sequenzbestimmung durch massenspektrometrie auf dem weg des abbaus mit exonuklease
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
WO1997029447A2 (en) 1996-02-09 1997-08-14 Adeza Biomedical Corporation Method for selecting medical and biochemical diagnostic tests using neural network-related applications
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
EP1027456B1 (en) 1997-10-31 2005-03-16 Affymetrix, Inc. (a Delaware Corporation) Expression profiles in adult and fetal organs
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6763307B2 (en) * 2000-03-06 2004-07-13 Bioseek, Inc. Patient classification
EP1380001A2 (en) * 2001-03-13 2004-01-14 Ashni Naturaceuticals, Inc. Method for association of genomic and proteomic pathways associated with physiological or pathophysiological processes
US8000949B2 (en) * 2001-06-18 2011-08-16 Genego, Inc. Methods for identification of novel protein drug targets and biomarkers utilizing functional networks
US7393656B2 (en) 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
US7415359B2 (en) 2001-11-02 2008-08-19 Gene Network Sciences, Inc. Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
DE60321689D1 (de) 2002-08-29 2008-07-31 Gene Network Sciences Inc Systeme und verfahren zum schliessen auf biologische netzwerke
CN1714371A (zh) 2002-11-19 2005-12-28 Gni美国公司 根据时间序列基因表达数据的基因网络的非线性模拟
US20070104688A1 (en) 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
JP4288345B2 (ja) * 2003-06-19 2009-07-01 独立行政法人産業技術総合研究所 新規てんかんモデル動物
EP1512970A1 (en) * 2003-09-05 2005-03-09 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Method for determining the impact of a multicomponent mixture on the biological profile of a disease
JPWO2005035780A1 (ja) 2003-10-14 2006-12-21 株式会社セルフリーサイエンス 指標物質の新規スクリーニング方法
EP2207033B1 (en) 2004-04-15 2014-06-18 University of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
US8185367B2 (en) 2004-04-30 2012-05-22 Merck Sharp & Dohme Corp. Systems and methods for reconstructing gene networks in segregating populations
EP1607898A3 (en) 2004-05-18 2006-03-29 Neal E. Solomon A bioinformatics system for functional proteomics modelling
GB0419124D0 (en) 2004-08-27 2004-09-29 Proteome Sciences Plc Methods and compositions relating to Alzheimer's disease
US20100316629A1 (en) 2004-09-01 2010-12-16 Shaughnessy Jr John D Use of gene expression profiling to predict survival in cancer patient
WO2006054991A1 (en) * 2004-11-17 2006-05-26 Immunivest Corporation Magnetic enrichment of circulating cells, fragments and debris for enabling hts proteomics and genomics in disease detection
JP2008528975A (ja) * 2005-01-24 2008-07-31 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ 細胞シグナル伝達系のモデリングのためのベイジアンネットワークの使用
US20080195570A1 (en) 2005-03-31 2008-08-14 Koninklijke Philips Electronics, N.V. System and Method for Collecting Evidence Pertaining to Relationships Between Biomolecules and Diseases
WO2006129401A1 (ja) * 2005-05-31 2006-12-07 Jcl Bioassay Corporation プロテオーム網羅的解析における特異的蛋白質のスクリーニング方法
US7906116B2 (en) * 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
EP2332984A3 (en) 2005-09-30 2011-10-12 Universiteit Maastricht Tumor angiogenesis associated genes and a method for their identification
EP1840574A1 (en) 2006-03-30 2007-10-03 Institut Pasteur Use of the alpha chain of brain spectrin and fragments thereof, for diagnosing cerebral diseases
US20080046290A1 (en) 2006-08-21 2008-02-21 Cerner Innovation, Inc. System and method for compiling and displaying discharge instructions for a patient
WO2008060620A2 (en) * 2006-11-15 2008-05-22 Gene Network Sciences, Inc. Systems and methods for modeling and analyzing networks
MX2009005651A (es) 2006-12-05 2009-06-08 Decode Genetics Ehf Marcadores geneticos para el manejo de riesgo de la arritmia cardiaca.
CN101105841B (zh) 2007-02-12 2011-06-15 浙江大学 由大规模基因芯片表达谱数据构建基因调控亚网络的方法
US8140270B2 (en) 2007-03-22 2012-03-20 National Center For Genome Resources Methods and systems for medical sequencing analysis
US20090117562A1 (en) 2007-04-09 2009-05-07 Valerie Wailin Hu Method and kit for diagnosing Autism using gene expression profiling
AU2008284225B2 (en) 2007-05-16 2013-06-06 Edsa Micro Corporation Real-time predictive systems for intelligent energy monitoring and management of electrical power networks
JP2009050171A (ja) * 2007-08-23 2009-03-12 Toyobo Co Ltd 表面プラズモン共鳴による基板上におけるリン酸化の検出方法
DE102007044380A1 (de) 2007-09-17 2009-03-19 Siemens Ag Verfahren zum rechnergestützten Lernen eines probabilistischen Netzes
US7895146B2 (en) 2007-12-03 2011-02-22 Microsoft Corporation Time modulated generative probabilistic models for automated causal discovery that monitors times of packets
WO2009082607A2 (en) 2007-12-04 2009-07-02 Alnylam Pharmaceuticals, Inc. Targeting lipids
WO2009105718A1 (en) 2008-02-20 2009-08-27 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism
US8173369B2 (en) 2008-05-15 2012-05-08 The Regents Of The University Of California Peripheral gene expression biomarkers for autism
US8005770B2 (en) 2008-06-09 2011-08-23 Microsoft Corporation Parallel generation of a bayesian network
UA104868C2 (uk) * 2008-08-15 2014-03-25 Меррімак Фармасьютікалз, Інк. Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції
CN102132280A (zh) 2008-08-15 2011-07-20 皇家飞利浦电子股份有限公司 模型增强的成像
US20110295782A1 (en) 2008-10-15 2011-12-01 Alexander Stojadinovic Clinical Decision Model
WO2010056374A2 (en) * 2008-11-17 2010-05-20 Veracyte, Inc. Methods and compositions of molecular profiling for disease diagnostics
US20110294693A1 (en) 2008-11-17 2011-12-01 The George Washington University Compositions and Methods for Identifying Autism Spectrum Disorders
AU2010247800A1 (en) 2009-05-11 2011-12-15 Berg Llc Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
US20110202486A1 (en) 2009-07-21 2011-08-18 Glenn Fung Healthcare Information Technology System for Predicting Development of Cardiovascular Conditions
WO2011031803A1 (en) 2009-09-08 2011-03-17 Nodality, Inc. Analysis of cell networks
US20110112380A1 (en) 2009-11-12 2011-05-12 eTenum, LLC Method and System for Optimal Estimation in Medical Diagnosis
US20130123124A1 (en) 2010-03-12 2013-05-16 Children's Medical Center Corporation Methods and compositions for characterizing autism spectrum disorder based on gene expression patterns
WO2011125917A1 (ja) * 2010-03-31 2011-10-13 国立大学法人熊本大学 統合プロテオーム解析用データ群の生成方法ならびに同生成方法にて生成した統合プロテオーム解析用データ群を用いる統合プロテオーム解析方法、およびそれを用いた原因物質同定方法
US10176541B2 (en) 2010-09-01 2019-01-08 Apixio, Inc. Medical information navigation engine (MINE) system
US11195213B2 (en) 2010-09-01 2021-12-07 Apixio, Inc. Method of optimizing patient-related outcomes
WO2012119129A1 (en) 2011-03-02 2012-09-07 Berg Biosystems, Llc Interrogatory cell-based assays and uses thereof
CN103107315B (zh) 2011-11-10 2016-03-30 北京有色金属研究总院 一种纳米硅碳复合材料及其制备方法
CA2866407A1 (en) 2012-03-05 2013-09-12 Berg Llc Compositions and methods for diagnosis and treatment of pervasive developmental disorder
MX375673B (es) 2012-04-02 2025-03-06 Berg Llc Ensayos basados en interrogatorios celulares y usos de los mismos.
EA201492178A1 (ru) 2012-05-22 2015-12-30 Берг Ллк Основанные на клетках перекрестные анализы для идентификации маркеров индуцированной лекарственными средствами токсичности
CA2960837A1 (en) 2014-09-11 2016-03-17 Berg Llc Bayesian causal relationship network models for healthcare diagnosis and treatment based on patient data

Also Published As

Publication number Publication date
JP2018033448A (ja) 2018-03-08
JP2015519876A (ja) 2015-07-16
EA038600B1 (ru) 2021-09-21
MX2014011797A (es) 2014-12-10
CN104520435A (zh) 2015-04-15
KR20140142357A (ko) 2014-12-11
US20130259847A1 (en) 2013-10-03
JP6189926B2 (ja) 2017-08-30
BR112014024537A2 (pt) 2017-08-08
AU2019200670A1 (en) 2019-02-21
WO2013151577A9 (en) 2014-11-20
SG11201406201YA (en) 2014-10-30
EP2834366A4 (en) 2016-04-27
EP2834366B1 (en) 2024-05-29
SG10201608234UA (en) 2016-11-29
IL234920B (en) 2019-12-31
NZ700647A (en) 2016-08-26
AU2019200670B2 (en) 2021-09-23
CA2869296A1 (en) 2013-10-10
US20190279736A1 (en) 2019-09-12
HK1209161A1 (en) 2016-03-24
WO2013151577A8 (en) 2014-12-31
AU2012376214B2 (en) 2019-02-14
US12437835B2 (en) 2025-10-07
WO2013151577A1 (en) 2013-10-10
KR102149070B1 (ko) 2020-10-15
JP6767320B2 (ja) 2020-10-14
CN108048521A (zh) 2018-05-18
NZ718138A (en) 2017-11-24
CN108048521B (zh) 2022-05-27
JP2021003121A (ja) 2021-01-14
AU2012376214A1 (en) 2014-10-30
EA201491833A1 (ru) 2015-01-30
CN110456035A (zh) 2019-11-15
EP2834366A1 (en) 2015-02-11
MX357392B (es) 2018-07-06
KR20200105524A (ko) 2020-09-07
IL234920A0 (en) 2014-12-31
US10061887B2 (en) 2018-08-28

Similar Documents

Publication Publication Date Title
MX375673B (es) Ensayos basados en interrogatorios celulares y usos de los mismos.
SG193006A1 (en) Interrogatory cell-based assays and uses thereof
BR112015001592A8 (pt) análise de imagem e medidas de amostras biológicas
UY34697A (es) Métodos para preparar análogos de nucleótidos
CL2015002372A1 (es) Un proceso para preparar un compuesto de fórmula (2-g) y (2-h) que comprende llevar a cabo la reducción enantioselectiva para obtener un compuesto de fórmula (3-c). un proceso para preparar un compuesto de fórmula (5-f). un proceso para preparar un compuesto de fórmula (m).
EP2926888A4 (en) SYSTEM FOR WASHING A MEMBRANE AND METHOD FOR WASHING A MEMBRANE THEREWITH
AR093377A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
UY34097A (es) Alineación de anticoagulante de cebado para extracción de sangre.
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
AR095774A1 (es) Anticuerpos anti-il-4 y anticuerpos biespecíficos y sus usos
EP2871466A4 (en) PORTAL STRUCTURE FOR USE IN A COMBINED MOBILE RADIATION PROTECTION SYSTEM
EP2874326A4 (en) PRODUCTION PROCESSES FOR RUSTIC CODE BOOK, BEAM SEARCH METHOD AND ASSOCIATED DEVICE
EP2983416A4 (en) RADIO PROCEDURE, DEVICE AND SYSTEM
BR112014032114A2 (pt) sistema de conversão de biomassa, e, método.
FR3003763B1 (fr) Gel alcalin oxydant de decontamination biologique et procede de decontamination biologique de surfaces utilisant ce gel.
BR112015001215A2 (pt) sistema de conversão de biomassa, e, método.
CR20150257A (es) Derivados de n-(piridin-2-il)pirimidin-4-amina que contiene un grupo sulfoximina
BR112014028744A2 (pt) sistema, e, método para fornecer á compensação de aceleração de um transdutor.
EP2926731A4 (en) MEDICAL LIGHT SOURCE AND MEDICAL LIGHT SOURCE SYSTEM THEREWITH
BR112015011678A2 (pt) sistema de informação baseado em código
EP2940385A4 (en) FIRE FUNERAL EQUIPMENT
EP3520162C0 (de) Brennstoffzellenmodul, brennstoffzellensystem sowie betriebsverfahren
BR112015004436A2 (pt) hidrogel, processo de obtenção de um hidrogel poroso, processo agrícola, e, sistema.
EP2763030A4 (en) DATABASE SYSTEM AND CONTROL PROCEDURE THEREFOR
UA112488C2 (uk) Три(гетеро)арилпіразоли і їх застосування